Hypoalphalipoproteinemia: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Chunbum Park
m (sub)
mNo edit summary
 
(6 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Hypoalphalipoproteinemias''', also called ''familial high density lipoprotein deficiency disease'' and ''HDL lipoprotein deficiency disease'', are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein a-i; lecithin cholesterol acyltransferase; and atp-binding cassette transporters."<ref name="MeSH-Hypoalphalipoproteinemias ">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=Hypoalphalipoproteinemias |title=Hypoalphalipoproteinemias |accessdate=2007-12-17 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>
'''Hypoalphalipoproteinemias''', also called ''familial high density lipoprotein deficiency disease'' and ''[[HDL]] lipoprotein deficiency disease'', are defined as "conditions with abnormally low levels of alpha-lipoproteins ([[high-density lipoprotein]]s) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding [[apolipoprotein A-I]]; [[lecithin cholesterol acyltransferase]]; and ATP-binding cassette transporters."<ref name="MeSH-Hypoalphalipoproteinemias">{{MeSH}}</ref> This causes [[hypertriglyceridemia]].


==Treatment==
==Treatment==
Using [[gemfibrozil]] to treat hypoalphalipoproteinemia may reduce major cardiovascular events<ref name="pmid10438259">{{cite journal |author=Rubins HB, Robins SJ, Collins D, ''et al'' |title=Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group |journal=N. Engl. J. Med. |volume=341 |issue=6 |pages=410–8 |year=1999 |pmid=10438259 |doi= |issn=|url=http://content.nejm.org/cgi/content/full/341/6/410}}</ref> and [[stroke]]<ref name="pmid11401940">{{cite journal |author=Bloomfield Rubins H, Davenport J, Babikian V, ''et al'' |title=Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) |journal=Circulation |volume=103 |issue=23 |pages=2828–33 |year=2001 |pmid=11401940 |doi= |issn=}}</ref> and  in men with known men with known [[coronary heart disease]].
Using [[gemfibrozil]] to treat hypoalphalipoproteinemia may reduce major cardiovascular events<ref name="pmid10438259">{{cite journal |author=Rubins HB, Robins SJ, Collins D, ''et al'' |title=Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group |journal=N. Engl. J. Med. |volume=341 |issue=6 |pages=410–8 |year=1999 |pmid=10438259 |doi= |issn=|url=http://content.nejm.org/cgi/content/full/341/6/410}}</ref> and [[stroke]]<ref name="pmid11401940">{{cite journal |author=Bloomfield Rubins H, Davenport J, Babikian V, ''et al'' |title=Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) |journal=Circulation |volume=103 |issue=23 |pages=2828–33 |year=2001 |pmid=11401940 |doi= |issn=}}</ref> and  in men with known men with known [[coronary heart disease]].
{{2x2-rx|major cardiovascular events|219|1045|275|992|1264|1267}}


Using [[simvastatin]] plus [[niacin]] to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with [[coronary heart disease]].<ref name="pmid11757504">{{cite journal |author=Brown BG, Zhao XQ, Chait A, ''et al'' |title=Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease |journal=N. Engl. J. Med. |volume=345 |issue=22 |pages=1583–92 |year=2001 |pmid=11757504 |doi= |issn=}}</ref>
Using [[simvastatin]] plus [[niacin]] to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with [[coronary heart disease]].<ref name="pmid11757504">{{cite journal |author=Brown BG, Zhao XQ, Chait A, ''et al'' |title=Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease |journal=N. Engl. J. Med. |volume=345 |issue=22 |pages=1583–92 |year=2001 |pmid=11757504 |doi= |issn=}}</ref>


==References==
==References==
<references/>
{{reflist}}[[Category:Suggestion Bot Tag]]
 
[[Category:CZ Live]] [[Category:Health Sciences Workgroup]]

Latest revision as of 17:00, 30 August 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Hypoalphalipoproteinemias, also called familial high density lipoprotein deficiency disease and HDL lipoprotein deficiency disease, are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein A-I; lecithin cholesterol acyltransferase; and ATP-binding cassette transporters."[1] This causes hypertriglyceridemia.

Treatment

Using gemfibrozil to treat hypoalphalipoproteinemia may reduce major cardiovascular events[2] and stroke[3] and in men with known men with known coronary heart disease.

Using simvastatin plus niacin to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with coronary heart disease.[4]

References

  1. Anonymous (2024), Hypoalphalipoproteinemia (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Rubins HB, Robins SJ, Collins D, et al (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259[e]
  3. Bloomfield Rubins H, Davenport J, Babikian V, et al (2001). "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)". Circulation 103 (23): 2828–33. PMID 11401940[e]
  4. Brown BG, Zhao XQ, Chait A, et al (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504[e]